(Hypertension. 1997;30:1544-1548.)
© 1997 American Heart Association, Inc.
Articles |
From the Department of Chemical Pathology, Prince of Wales Hospital, Shatin, NT, Hong Kong (C.S.H.) and the Department of Chemical Pathology, UMDS, Guy's & St Thomas' Hospital, London, UK (A.B., Y.K.S., R.S.).
Correspondence to Prof R. Swaminathan, Department of Chemical Pathology, United Medical & Dental Schools, St Thomas' Hospital, London, SE1 7EH UK. E-mail r.swaminathan{at}umds.ac.uk
Abstract The effect of carbidopa, a competitive inhibitor of dopamine synthesis on the excretion of sodium, dopamine (DA), and endogenous sodium transport inhibitor (ESTI), was examined in rats on normal and high salt diets for 7 days. ESTI activity was measured (1) as ouabain-like substance (OLS) by radioimmunoassay using an antibody raised against ouabain, (2) by inhibition of purified Na+,K+-ATPase activity (ATPI), and (3) as digoxin-like substance (DLS) using a commercial digoxin assay. The OLS immunoassay was validated against rubidium transport studies. High salt diet caused an increase in OLS and ATPI but not DLS. Sodium excretion in rats on normal sodium intake was not affected by carbidopa treatment but was significantly lower in the high sodium diet group during the first 5 days of the study. In the low salt group, carbidopa treatment caused significant increases in OLS. We conclude that ESTI (measured as OLS) and DA are important in the natriuresis of salt loading.
Key Words: dopamine sodium ouabain carbidopa sodium transport inhibitor, endogenous
This article has been cited by other articles:
![]() |
A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |